StockData
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. (ALLO) income statement

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.67−0.03 (-4.17%)

Close on Nov 19, 2026Market cap $230.41MP/E –Yield 0.00%

See a number that looks wrong?